Study: Tocilizumab reduces risk for death in hospitalized patients with severe COVID-19
Treatment with the rheumatoid arthritis drug tocilizumab, sold as Actemra, reduces risk for death among hospitalized patients with severe COVID-19 by about 30%, a study published Tuesday by JAMA Internal Medicine found.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
More News: Actemra | Arthritis | COVID-19 | Health | Internal Medicine | Rheumatoid Arthritis | Rheumatology | Study